These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 15164169

  • 1. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group.
    Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M.
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [Abstract] [Full Text] [Related]

  • 5. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group.
    JAMA; 2003 Jul 23; 290(4):486-94. PubMed ID: 12876091
    [Abstract] [Full Text] [Related]

  • 6. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.
    Kaiser T, Sawicki PT.
    Diabetologia; 2004 Mar 23; 47(3):575-580. PubMed ID: 14727025
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group.
    Lancet; 2002 Jun 15; 359(9323):2072-7. PubMed ID: 12086760
    [Abstract] [Full Text] [Related]

  • 10. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S, Chiasson JL.
    Curr Opin Pharmacol; 2005 Apr 15; 5(2):184-9. PubMed ID: 15780829
    [Abstract] [Full Text] [Related]

  • 11. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
    Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T.
    Stroke; 2004 May 15; 35(5):1073-8. PubMed ID: 15073402
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
    Holman RR, Bethel MA, Chan JC, Chiasson JL, Doran Z, Ge J, Gerstein H, Huo Y, McMurray JJ, Ryden L, Liyanage W, Schröder S, Tendera M, Theodorakis MJ, Tuomilehto J, Yang W, Hu D, Pan C, ACE Study Group.
    Am Heart J; 2014 Jul 15; 168(1):23-9.e2. PubMed ID: 24952856
    [Abstract] [Full Text] [Related]

  • 15. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN, Weickert MO, Pivovarova O, Bernigau W, Pfeiffer AF.
    Diabetes Technol Ther; 2011 Jun 15; 13(6):615-23. PubMed ID: 21488802
    [Abstract] [Full Text] [Related]

  • 16. [Progress in the prevention of type 2 diabetes].
    Schernthaner G.
    Wien Klin Wochenschr; 2003 Nov 28; 115(21-22):745-57. PubMed ID: 14743578
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Acarbose for patients with hypertension and impaired glucose tolerance.
    Rosenthal JH.
    JAMA; 2003 Dec 17; 290(23):3066; author reply 3067-9. PubMed ID: 14679262
    [No Abstract] [Full Text] [Related]

  • 19. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
    Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL.
    Diab Vasc Dis Res; 2009 Jan 17; 6(1):32-7. PubMed ID: 19156626
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.